Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Newron Pharmaceuticals SpA
Discovers and develops small molecule drugs

Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain.

The focus of its treatments includes patients with Parkinson's disease, Rett Syndrome, Amyotrophic Lateral Sclerosis, schizoprenia, and neuropathic pain.

The company was founded by Luca Benatti, Ruggero Fariello, and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Number of employees : 23 persons.
Sales per Businesses
20152016Delta
CHF (in Million)%CHF (in Million)%
Pharmaceutical Drugs2.43100%5.16100% +112.52%
Sales per Regions
20152016Delta
CHF (in Million)%CHF (in Million)%
Global2.43100%5.16100% +112.52%
Managers
NameAgeSinceTitle
Stefan Weber522005Chief Executive Officer, Director & IR Contact
Ulrich Köstlin, PhD652013Non-Executive Chairman
Roberto Galli-2002Vice President-Finance
Ravi Anand, MD602005Chief Medical Officer
Patrick J. Langlois, PhD722008Independent Non-Executive Director
Robert Leslie Holland MD, PhD622013Independent Non-Executive Director
Bo Jesper Hansen MD, PhD592013Independent Non-Executive Director
Joseph Donald deBethizy, PhD662014Independent Non-Executive Director
Luca Benatti, PhD562014Independent Non-Executive Director
Marco Caremi602002Executive Vice President-Business Development
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 15,814,543 11,593,513 73.3% 0 0.0% 73.3%
Shareholders
NameEquities%
Investor AB 1,772,817 11.2%
Gefim SpA 1,311,957 8.30%
Aviva Plc 1,097,054 6.94%
JPMorgan Asset Management (UK) Ltd. 311,633 1.97%
UBS AG (Investment Management) 273,806 1.73%
Union Investment Privatfonds GmbH 149,140 0.94%
Polar Capital LLP 147,270 0.93%
Norges Bank Investment Management 121,793 0.77%
Credit Suisse AG 113,934 0.72%
EFG Asset Management (UK) Ltd. 110,000 0.70%
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
NEWRON PHARMACEUTICALS SPA0.00%334
AMGEN23.84%133 151
CELGENE CORPORATION19.08%107 629
GILEAD SCIENCES3.00%97 208
REGENERON PHARMACEUTICALS40.54%55 401
VERTEX PHARMACEUTICALS121.49%41 373
ACTELION20.18%30 359
GENMAB22.59%13 517
EXELIXIS, INC.88.53%8 223
TESARO INC-1.87%6 995
BIOVERATIV INC0.00%6 881
KITE PHARMA INC151.96%6 389
BLUEBIRD BIO INC61.83%4 467
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.-22.94%4 321
NEUROCRINE BIOSCIENCES, INC.21.63%4 288
CLOVIS ONCOLOGY INC95.95%4 193
HUALAN BIOLOGICAL ENGINEERING INC--.--%3 865
BIOCON LTD26.47%3 720
PEPTIDREAM INC-43.42%3 601
INTERCEPT PHARMACEUTICALS INC18.21%3 212
JUNO THERAPEUTICS INC59.42%3 188
Connections : Newron Pharmaceuticals SpA
DFC Langlois
Azanta A/S
Oxford Gene Technology IP Ltd.
EryDel SpA
Early Clinical Development Consulting Ltd.
White City Consulting ApS
Karolinska Development AB (Private Equity)
NOXXON Pharma AG
LABORIE Medical Technologies, Inc.
Constantia Flexibles Group GmbH
Wellington Partners GmbH
PJL Consulting
European School of Management & Technology GmbH
Assobiotec
Proterris, Inc.
Constantia Flexibles AG
Universitätsklinikum Würzburg
Orphazyme ApS
Italian Angels For Biotech
CMC Contrast AB
MipSalus ApS
The European Association for Bioindustries
Company contact information
Newron Pharmaceuticals SpA
via Ludovico Ariosto 21
Bresso, Milan 20091

Phone : +39.02.610.3461
Fax : +39.02.610.34654
Web : www.newron.com
© 2017 People , Fundamentals and Ownership